Arthrocentesis and viscosupplementation as treatment modalities for arthralgia of the temporomandibular joint by Vos, Lukas Matthijs
  
 University of Groningen
Arthrocentesis and viscosupplementation as treatment modalities for arthralgia of the
temporomandibular joint
Vos, Lukas Matthijs
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2014
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Vos, L. M. (2014). Arthrocentesis and viscosupplementation as treatment modalities for arthralgia of the
temporomandibular joint. [S.l.]: [S.n.].
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the







In absence of clear knowledge of the exact pathophysiology and risk factors for arthralgia 
of the temporomandibular joint (TMJ), 1 treatment is usually focused on pain relieve and 
regaining mandibular function. However, treatment duration and outcome are usually 
hard to predict. The general aim of this thesis was to investigate the clinical and cost 
effectiveness of arthrocentesis as initial treatment and explore the applicability in the 
TMJ of a related therapeutic treatment modality that proved to be successful in treating 
arthralgia of the knee joint, i.e. viscosupplementation.
 In this chapter the results of this thesis are discussed and placed into a broader clinical 
and economical perspective. Furthermore, future research directions are considered, 
especially with regard to intra-articular fluid analysis and the role of minimally invasive 
procedures in the treatment strategy of arthralgia of the TMJ.
Arthrocentesis as initial treatment modality
The effectiveness of arthrocentesis as treatment modality for TMJ arthropathy has been 
extensively described in the literature. Success rates up to 91% have been reported for 
the use of arthrocentesis in anterior disc displacement without reduction. 2 Although 
evidence is still inconclusive, it seems that arthrocentesis has indeed a beneficial effect 
on pain and impairment of mandibular motion. 3-8 Al-Belasy and Dolwick concluded 
that arthrocentesis is a highly efficient procedure with low morbidity. 7 The results of 
the systematic review described in chapter 2 indicate that lavage of the TMJ is slightly 
more effective than non-surgical treatment with regard to pain reduction. However, the 
available evidence does not substantially support superiority of TMJ lavage, especially 
with regard to improvement of mandibular movement.
 Currently, treatment of TMJ arthralgia usually starts with non-invasive treatment. 
Only when the result of this treatment is not satisfactory invasive treatment modalities 
are considered. This order seems to be mainly based on the non-invasive and supposed 
reversible nature of conventional therapy and does not seem to be substantiated 
by scientific evidence. Arthrocentesis (often supplemented with injection of anti-
inflammatory substances, such as corticosteroids) and arthroscopic surgical procedures 
have shown to be effective even when conventional therapy is not satisfactory. 
Arthrocentesis is considered to be a highly efficient procedure with low morbidity. 7 
Therefore, it seems reasonable to reconsider the role of arthrocentesis in the treatment 
strategy of TMJ arthropathy.
 The results of the randomized controlled trial described in chapter 3 indicate that it is 
the lavage of the joint space that mainly accounts for the effectiveness of the treatment, 
regardless the addition of dexamethasone. Although dexamethasone modifies the 
vascular response during the inflammatory process and inhibits destructive enzymes 
and the actions of inflammatory cells, 9 this study suggests that the possible effect of 
additional dexamethasone was not clinically relevant. In the study design, arthrocentesis 
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was applied as initial treatment. Under this experimental condition, in both groups the 
TMJ pain declined, maximum interincisal opening (MIO) improved, and the Mandibular 
Function Impairment Questionnaire (MFIQ) score decreased. However, this study was not 
designed to investigate the effectiveness of arthrocentesis as initial treatment. Moreover, 
the sample size was too small to be able to allow firm conclusions in this regard. Therefore, 
based on the promising results of this study, an additional randomized controlled trial 
was conducted to investigate the effectiveness of arthrocentesis as initial treatment 
compared to the conventional treatment approach, which was referred to as ‘care as 
usual’ (CAU). This study is reported in detail in chapter 4. In particular, TMJ pain seemed 
to decrease more rapidly after arthrocentesis as compared to CAU. Furthermore, when 
considered in economical perspective as is described in chapter 5, the results suggest 
that arthrocentesis as compared to CAU is the best initial therapy for the treatment of TMJ 
arthralgia. Arthrocentesis seems to be associated with better health outcomes and lower 
costs than CAU.
 Although additional studies are indicated to allow more definitive conclusions, based 
on these four chapters, it is doubtful whether conventional care should still be preferred as 
initial therapy, since its indication is probably mainly based on its non-invasive character 
and is lacking scientific evidence. Therefore, the treatment order for TMJ arthralgia, in 
which conventional treatment is offered first, as is suggested in currently available 
guidelines (AAOP guidelines for orofacial pain, ASTMJS guidelines, RCDSO guidelines for 
diagnosis and treatment of TMD) should be reconsidered.
Pathophysiology of TMJ arthropathy
In order to develop effective treatment modalities or strategies, it is important to 
understand the pathophysiological mechanisms involved. Therefore, many studies have 
been conducted to investigate different parts of the pathophysiological mechanisms 
involved in TMJ arthralgia. 10-14 However, still most of the current understanding of the 
pathophysiology of arthropathies, e.g. articular cartilage maintenance and degradation, is 
derived from large joints, in particular the knee joint. One of the most prominent theories 
in this context is the ‘hypoxia-reperfusion injury’ theory, which is stated in many textbooks 
on this subject. However, the few studies that could be included in the systematic review 
described in chapter 6 did not provide any evidence to support or reject the hypothesis 
that hypoxia-reperfusion plays a (major) role in TMJ osteoarthritis. Positive but weak 
evidence supports the hypothesis that hypoxia-reperfusion injury occurs in osteoarthritis 
in the knee.
 An important difference between the TMJ and the knee joint is the type of cartilage 
that forms the articular lining. In the TMJ the fibrocartilage lining predominantly contains 
collagen type I, whereas hyaline cartilage in the knee joint mainly consists of collagen 
type II. However, the results of the study that was described in chapter 7 indicate that 
the relative concentrations of specific markers for type I en II collagen degradation, CTX-I 
and II respectively, did not significantly differ between the two joints. The inflammatory 
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component was more distinct in osteoarthritis of the TMJ as compared to the knee joint. 
According to these findings, the type of collagen seems to be of minor importance when 
comparing TMJ and knee joint osteoarthritis. However, the more prominent role of the 
inflammation marker, i.e. PGE2, suggests differences in pathophysiology between the TMJ 
and the knee joint. Therefore, results obtained from research in the knee joint should not 
be applied to the TMJ indiscriminately.
 The same markers were investigated in chapter 8, where a comparison was made 
between TMJ osteoarthritis and healthy symptom-free joints. Assumed changes in 
synovial fluid concentrations of CTX-I, CTX-II, cartilage oligomeric matrix protein (COMP) 
and PGE2 seem to occur proportionally, indicating that more distinct inflammation is 
accompanied by more cartilage degradation. These findings are consistent with findings 
in knee joint osteoarthritis. 15 Furthermore, an unexpected large contribution of CTX-II 
in TMJ osteoarthritis was found, both in chapters 7 and 8. Although the fibrocartilage 
lining in the TMJ mainly consists of type I collagen, the superficial layer of the articular 
fibrocartilage may contain more collagen type II than the inner part, especially with 
regard to the articular disc. 16 Therefore, CTX-II may be useful to quantify the activity of 
cartilage degradation in TMJ OA.
Viscosupplementation
In order to sufficiently investigate the effectiveness of treatment options for TMJ arthralgia 
it is essential, according to the current standards, to obtain evidence using a randomized, 
double blind, placebo controlled trial research design. However, for therapeutic options 
that consist of the intra-articular application of therapeutic agents, such a research design 
has still not been reported. In chapter 9 a technique is described that may allow a double 
blind, placebo controlled design. Although the technique was described in a case report, 
its feasibility seems promising. Furthermore, the application scheme, that was derived 
from investigations in the knee joint, 17 seems to have a beneficial effect on the health 
outcome as well, although the reported case was a severe of chronic TMJ pain.
Conclusions
Based on evidence available in the literature and the results described in this thesis, a more 
prominent place for arthrocentesis in the treatment TMJ arthralgia appears to be justified. 
The indication of arthrocentesis as initial treatment results in better health outcomes, 
especially with regard to pain reduction, and also may contribute to the reduction of 
healthcare costs. However, since the clinical effectiveness of arthrocentesis and CAU as 
initial treatment did not differ significantly over time, this new treatment strategy is not 
likely to decrease the number of cases that remain symptomatic. Therefore, modification 
of existing treatment modalities or development of novel therapeutic options is 
necessary to increase the clinical effectiveness. Hereby treatment options that have been 
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tested in larger synovial joints may serve as a starting point. However, thoroughly testing 
of these treatment modalities in the TMJ itself remains needed, because differences in 
pathophysiology between the TMJ and other joints may influence the clinical results.
Future perspectives
In general, and parallel to clinical effectiveness, cost effectiveness is becoming an 
important focus in medicine. This also applies to the treatment of TMJ disorders. Causal 
therapy is not yet within reach, because the pathophysiology is still not clear. Therefore, 
exploration and testing of hypotheses with regard to pathologic mechanisms that may be 
involved in TMJ diseases still remains essential in order to develop more targeted treatment 
modalities. Meanwhile, modification of the treatment strategy may result in improvement 
of clinical effectiveness as well as in cost reduction. Investigating the influence of applying 
arthrocentesis as initial therapy was a first step towards a more cost effective approach in 
the management of TMJ arthralgia. An international multicentre randomized controlled 
trial investigating the clinical and cost effectiveness of arthrocentesis as initial treatment 
may allow more definite conclusions to substantiate reconsideration of the international 
guidelines for the treatment of arthralgia and may facilitate implementation if guidelines 
are revised.
 Based on the results of research performed in the knee joint, a possible additional step 
may be to test the effectiveness of viscosupplementation in TMJ arthralgia in a double 
blind, placebo controlled trial. Subsequently, when viscosupplementation would appear 
to be effective in the TMJ as well, its role has to be determined in order to further improve 
cost effectiveness in the management of TMJ arthralgia.
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